Crohn’s patients show improvement with new drug
A new treatment for Crohn’s disease has shown promising results in a recently completed phase III clinical trial.

According to results published in the New England Journal of Medicine, a drug called ustekinumab has resulted in significant improvement for patients with moderate to severe Crohn’s disease, compared with current treatments, which often have limited efficacy and can carry an increased risk of infection. Ustekinumab is currently used by individuals with psoriasis and psoriatic arthritis to block interleukin-12 and interleukin-23 proteins, which are involved in the inflammatory response.

Data from the recent trial, which included more than 1,300 participants, showed that patients receiving ustekinumab instead of a placebo showed significantly better results in terms of both showing a clinical response and maintaining remission. Adverse side effects were not substantially different between groups of participants....